… molecular subtype of non-small-cell lung cancer (NSCLC) [6]. … KRAS mutations are almost
exclusively detected in lung adenocarcinomas and are rarely found in squamous-cell cancers […

… KRAS mutations in non-small-cell lung cancer by describing the biological structure of KRAS
and exploring the clinical relevance of KRAS … the treatment of KRAS-mutant lung cancers. …

… , effective KRAS-targeted therapies still remain elusive. KRAS mutant lung cancers have
worse … the critical need for novel agents targeting KRAS-driven NSCLC. Numerous therapeutic …

… inhibitors, independent of tumor mutational burden. As our … mutations occurring in the
context of KRAS mutations have a worse clinical course than other patients with KRAS-mutant …

… with and without KRAS mutation. An association between PD-L1 expression and ICI efficacy
was found in KRAS-mutant NSCLC. The efficacy of ICIs against all mutation types did not …

… inhibition, and emerging direct inhibitors of K-Ras which will soon be combined with …
that KRAS mutant NSCLC will be the most important molecular subset of cancer to evaluate …

… EGFR mutations in lung cancer (4–9). Below, we focus on the role of KRAS mutations in this
… Recently, we evaluated the frequency of KRAS mutations in lung adenocarcinomas from …

… To provide an overview of the epidemiology and prognostic and predictive value of KRAS
mutations in non–small-cell lung cancer (NSCLC), summarizing current treatment approaches …

… For example, 17% of all lung cancers have KRas mutations; of these KRas-mutated … trials
in non–small cell lung cancer (NSCLC) may need to consider the specific KRas point mutation. …

… on survival in lung cancer. In this meta-analysis, the presence of KRAS mutations was a
negative prognostic factor for OS (p = 0.01). In adenocarcinoma, KRAS was prognostic for OS (…